Kiromic BioPharma (KRBP) Competitors $1.27 +0.18 (+16.51%) As of 09:30 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsTrends KRBP vs. PHIO, ABVC, BCLI, SLXN, ADXN, NEUP, TRAW, AIM, QNTM, and TSBXShould you be buying Kiromic BioPharma stock or one of its competitors? The main competitors of Kiromic BioPharma include Phio Pharmaceuticals (PHIO), ABVC BioPharma (ABVC), Brainstorm Cell Therapeutics (BCLI), Silexion Therapeutics (SLXN), Addex Therapeutics (ADXN), Neuphoria Therapeutics Inc. - Common Stock (NEUP), Traws Pharma (TRAW), AIM ImmunoTech (AIM), Quantum Biopharma (QNTM), and Turnstone Biologics (TSBX). These companies are all part of the "pharmaceutical products" industry. Kiromic BioPharma vs. Phio Pharmaceuticals ABVC BioPharma Brainstorm Cell Therapeutics Silexion Therapeutics Addex Therapeutics Neuphoria Therapeutics Inc. - Common Stock Traws Pharma AIM ImmunoTech Quantum Biopharma Turnstone Biologics Kiromic BioPharma (NASDAQ:KRBP) and Phio Pharmaceuticals (NASDAQ:PHIO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership, community ranking and media sentiment. Does the MarketBeat Community believe in KRBP or PHIO? Phio Pharmaceuticals received 36 more outperform votes than Kiromic BioPharma when rated by MarketBeat users. Likewise, 63.79% of users gave Phio Pharmaceuticals an outperform vote while only 50.00% of users gave Kiromic BioPharma an outperform vote. CompanyUnderperformOutperformKiromic BioPharmaOutperform Votes150.00% Underperform Votes150.00% Phio PharmaceuticalsOutperform Votes3763.79% Underperform Votes2136.21% Does the media prefer KRBP or PHIO? In the previous week, Phio Pharmaceuticals had 2 more articles in the media than Kiromic BioPharma. MarketBeat recorded 2 mentions for Phio Pharmaceuticals and 0 mentions for Kiromic BioPharma. Phio Pharmaceuticals' average media sentiment score of 0.22 beat Kiromic BioPharma's score of 0.00 indicating that Phio Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Kiromic BioPharma Neutral Phio Pharmaceuticals Neutral Do analysts rate KRBP or PHIO? Phio Pharmaceuticals has a consensus price target of $4.00, indicating a potential upside of 196.30%. Given Phio Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Phio Pharmaceuticals is more favorable than Kiromic BioPharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kiromic BioPharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Phio Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, KRBP or PHIO? Kiromic BioPharma has a beta of 1.66, meaning that its share price is 66% more volatile than the S&P 500. Comparatively, Phio Pharmaceuticals has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500. Do insiders & institutionals have more ownership in KRBP or PHIO? 10.9% of Kiromic BioPharma shares are held by institutional investors. Comparatively, 57.3% of Phio Pharmaceuticals shares are held by institutional investors. 20.6% of Kiromic BioPharma shares are held by company insiders. Comparatively, 0.6% of Phio Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is KRBP or PHIO more profitable? Kiromic BioPharma's return on equity of 0.00% beat Phio Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Kiromic BioPharmaN/A N/A -277.46% Phio Pharmaceuticals N/A -134.57%-108.39% Which has stronger valuation & earnings, KRBP or PHIO? Kiromic BioPharma is trading at a lower price-to-earnings ratio than Phio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKiromic BioPharmaN/AN/A-$26.90M-$3.50-0.36Phio PharmaceuticalsN/AN/A-$10.83M-$10.92-0.12 SummaryPhio Pharmaceuticals beats Kiromic BioPharma on 11 of the 15 factors compared between the two stocks. Remove Ads Get Kiromic BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for KRBP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KRBP vs. The Competition Export to ExcelMetricKiromic BioPharmaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.95M$3.07B$5.64B$8.08BDividend YieldN/A1.47%4.89%4.04%P/E Ratio-0.3627.6723.7318.99Price / SalesN/A374.75381.75120.64Price / CashN/A168.6838.0534.64Price / Book-0.153.466.904.26Net Income-$26.90M-$71.72M$3.18B$247.00M7 Day Performance-15.33%-1.93%6.23%-2.60%1 Month Performance7.63%-8.69%1.18%-8.62%1 Year Performance-39.52%-22.86%12.45%2.07% Kiromic BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KRBPKiromic BioPharmaN/A$1.27+16.5%N/A-36.2%$1.95MN/A-0.3660Gap UpPHIOPhio Pharmaceuticals2.5851 of 5 stars$1.32-7.0%$4.00+203.0%-85.8%$9.09MN/A-0.1210Short Interest ↑ABVCABVC BioPharma0.5986 of 5 stars$0.69+0.0%N/A-46.3%$8.96M$509,788.00-0.8030Short Interest ↑Positive NewsBCLIBrainstorm Cell Therapeutics4.1144 of 5 stars$1.56-2.5%$30.00+1,823.1%-66.8%$8.90MN/A-0.3340Analyst ForecastNews CoverageGap UpSLXNSilexion TherapeuticsN/A$1.05-1.9%$9.00+757.1%N/A$8.84MN/A0.00N/AADXNAddex Therapeutics2.8196 of 5 stars$8.24-3.1%$30.00+264.1%-38.7%$8.73M$556,045.00-24.2330Short Interest ↓Positive NewsNEUPNeuphoria Therapeutics Inc. - Common Stock2.1455 of 5 stars$4.93-5.2%$21.00+326.0%N/A$8.66M$662,715.000.00N/AUpcoming EarningsTRAWTraws Pharma1.1924 of 5 stars$2.29-30.8%N/AN/A$8.36M$226,000.00-0.0217Short Interest ↓Gap DownHigh Trading VolumeAIMAIM ImmunoTech2.3834 of 5 stars$0.12-11.0%$2.75+2,189.8%-65.3%$8.26M$190,000.00-0.2620Gap UpQNTMQuantum BiopharmaN/A$4.30-5.5%N/AN/A$8.25MN/A-0.28N/ATSBXTurnstone Biologics2.3982 of 5 stars$0.36-8.0%$0.45+26.8%-88.4%$8.21M$19.31M-0.1182Short Interest ↑Positive News Remove Ads Related Companies and Tools Related Companies PHIO Competitors ABVC Competitors BCLI Competitors SLXN Competitors ADXN Competitors NEUP Competitors TRAW Competitors AIM Competitors QNTM Competitors TSBX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KRBP) was last updated on 3/12/2025 by MarketBeat.com Staff From Our PartnersAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredWarning: What they're not telling you about these recent selloffsIn light of massive recent selloffs... our senior analyst Dan Ferris has issued a new warning for the American...Stansberry Research | SponsoredSilent Raid on IRAs and 401(k)s Begins—Are You Next?Look around—everything feels oddly steady. Gas prices aren't skyrocketing. Banks aren't collapsing. The mar...Genesis Gold Group | SponsoredMagnificent 7 wipeout: What's next?A massive wave of volatility is sweeping the stock market... After the recent selloff, the "Magnificent Sev...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiromic BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiromic BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
